{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T13:42:54Z","timestamp":1762177374602,"version":"build-2065373602"},"reference-count":19,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Urol\u00f3gicas Espa\u00f1olas"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.acuro.2020.06.016","type":"journal-article","created":{"date-parts":[[2021,1,30]],"date-time":"2021-01-30T23:10:19Z","timestamp":1612048219000},"page":"215-219","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Eficacia y seguridad de la colagenasa de Clostridium histolyticum en la enfermedad de Peyronie seg\u00fan un protocolo de tratamiento modificado"],"prefix":"10.1016","volume":"45","author":[{"given":"E.","family":"Garc\u00eda Cruz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Mercader Barrull","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Camacho Rovira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Alcaraz Asensio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.acuro.2020.06.016_bib0100","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0022-5347(06)00270-9","article-title":"An analysis of the natural history of Peyronie's disease","volume":"175","author":"Mulhall","year":"2006","journal-title":"J Urol."},{"key":"10.1016\/j.acuro.2020.06.016_bib0105","doi-asserted-by":"crossref","first-page":"e0150157","DOI":"10.1371\/journal.pone.0150157","article-title":"The prevalence of Peyronie's disease in the United States: A population-based study","volume":"11","author":"Stuntz","year":"2016","journal-title":"PLoS One."},{"key":"10.1016\/j.acuro.2020.06.016_bib0110","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/ncpuro0201","article-title":"Mechanisms of disease: New insights into the cellular and molecular pathology of Peyronie's disease","volume":"2","author":"Gonzalez-Cadavid","year":"2005","journal-title":"Nat Clin Pract Urol."},{"year":"2018","series-title":"EAU guidelines on erectile dysfunction, premature ejaculation, penile curvature and priapism","author":"Hatzimouratidis","key":"10.1016\/j.acuro.2020.06.016_bib0115"},{"key":"10.1016\/j.acuro.2020.06.016_bib0120","first-page":"107","article-title":"Role of collagenase Clostridium histolyticum in Peyronie's disease","volume":"9","author":"Peak","year":"2015","journal-title":"Biologics."},{"key":"10.1016\/j.acuro.2020.06.016_bib0125","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1016\/j.juro.2012.01.032","article-title":"Phase 2b study of the clinical efficacy and safety of collagenase Clostridium histolyticum in patients with Peyronie disease","volume":"187","author":"Gelbard","year":"2012","journal-title":"J Urol."},{"key":"10.1016\/j.acuro.2020.06.016_bib0130","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.juro.2013.01.087","article-title":"Clinical efficacy, safety and tolerability of collagenase Clostridium histolyticum for the treatment of Peyronie's disease in 2 large double-blind, randomized, placebo-controlled phase 3 studies","volume":"190","author":"Gelbard","year":"2013","journal-title":"J Urol."},{"key":"10.1016\/j.acuro.2020.06.016_bib0135","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.juro.2015.10.065","article-title":"Restoration of penile function and patient satisfaction with intralesional collagenase Clostridium histolyticum injection for Peyronie's disease","volume":"195","author":"Ziegelmann","year":"2016","journal-title":"J Urol."},{"key":"10.1016\/j.acuro.2020.06.016_bib0140","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1111\/bju.14784","article-title":"Optimizing collagenase Clostridium histolyticum therapy for Peyronie's disease using a novel approach with percutaneous needle tunnelling","volume":"124","author":"Fern\u00e1ndez-Pascual","year":"2019","journal-title":"BJU Int."},{"key":"10.1016\/j.acuro.2020.06.016_bib0145","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/bju.13932","article-title":"Safety and effectiveness of collagenase Clostridium histolyticum in the treatment of Peyronie's disease using a new modified shortened protocol","volume":"120","author":"Abdel-Raheem","year":"2017","journal-title":"BJU Int."},{"key":"10.1016\/j.acuro.2020.06.016_bib0150","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/j.1743-6109.2010.02124.x","article-title":"Linguistic and psychometric validation of the Erection Hardness Score to Spanish","volume":"8","author":"Garc\u00eda-Cruz","year":"2011","journal-title":"J Sex Med."},{"key":"10.1016\/j.acuro.2020.06.016_bib0155","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/j.1743-6109.2008.01081.x","article-title":"Peyronie's disease intervention trials: Methodological challenges and issues","volume":"6","author":"Muller","year":"2009","journal-title":"J Sex Med."},{"key":"10.1016\/j.acuro.2020.06.016_bib0160","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.sxmr.2017.03.005","article-title":"Collagenase Clostridium histolyticum in the treatment of urologic disease: Current and future impact","volume":"6","author":"Gabrielson","year":"2018","journal-title":"Sex Med Rev."},{"key":"10.1016\/j.acuro.2020.06.016_bib0165","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/andr.12497","article-title":"Collagenase Clostridium histolyticum for the treatment of Peyronie's disease: A prospective Italian multicentric study","volume":"6","author":"Capece","year":"2018","journal-title":"Andrology."},{"key":"10.1016\/j.acuro.2020.06.016_bib0170","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/JU.0000000000000245","article-title":"Outcomes of a novel penile traction device in men with Peyronie's disease: A randomized, single-blind, controlled trial","volume":"202","author":"Ziegelmann","year":"2019","journal-title":"J Urol."},{"key":"10.1016\/j.acuro.2020.06.016_bib0175","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.jsxm.2019.03.007","article-title":"Efficacy of combined collagenase Clostridium histolyticum and RestoreX penile traction therapy in men with Peyronie's disease","volume":"16","author":"Alom","year":"2019","journal-title":"J Sex Med."},{"key":"10.1016\/j.acuro.2020.06.016_bib0180","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.urology.2016.04.049","article-title":"Peyronie's disease and injectable collagenase Clostridium histolyticum: Safety, efficacy, and improvements in subjective symptoms","volume":"94","author":"Yang","year":"2016","journal-title":"Urology."},{"key":"10.1016\/j.acuro.2020.06.016_bib0185","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.urology.2016.09.050","article-title":"Impact of number of cycles of collagenase Clostridium histolyticum on outcomes in patients with Peyronie's disease","volume":"100","author":"Anaissie","year":"2017","journal-title":"J Urol."},{"key":"10.1016\/j.acuro.2020.06.016_bib0190","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.jsxm.2017.08.008","article-title":"Safety and efficacy of collagenase Clostridium histolyticum in the treatment of acute-phase Peyronie's disease","volume":"14","author":"Nguyen","year":"2017","journal-title":"J Sex Med."}],"container-title":["Actas Urol\u00f3gicas Espa\u00f1olas"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210480621000012?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210480621000012?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T12:36:31Z","timestamp":1759322191000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0210480621000012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S0210480621000012"],"URL":"https:\/\/doi.org\/10.1016\/j.acuro.2020.06.016","relation":{},"ISSN":["0210-4806"],"issn-type":[{"type":"print","value":"0210-4806"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Eficacia y seguridad de la colagenasa de Clostridium histolyticum en la enfermedad de Peyronie seg\u00fan un protocolo de tratamiento modificado","name":"articletitle","label":"Article Title"},{"value":"Actas Urol\u00f3gicas Espa\u00f1olas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acuro.2020.06.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 AEU. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}